Startup profile · funding coverage
Earli
Synthetic biopsy biotech forcing tumors to produce detectable biomarkers for ultra-early cancer localization.
Stage
series a
Status
private
Coverage
full
Why Earli is interesting
a16z Bio led seed; Khosla led Series A with Menlo — Stanford-licensed platform now advancing toward clinic.
Key facts
- Series A (Jan 2021): $40M led by Khosla; a16z and Menlo participated (BusinessWire)
- Seed (2018): $19.5M led by a16z Bio + Health and Marc Benioff; Menlo joined (BusinessWire)
Investors in our directory
Funds linked from Earli's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Healthtech
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Earli
Funding context and why this company shows up in venture coverage.
Earli's synthetic biopsy platform genetically programs tumors to emit biomarkers detectable in blood or imaging — aiming to find cancer earlier and localize it precisely.
Andreessen Horowitz (/fund/andreessen-horowitz) led the $19.5M seed. Khosla Ventures (/fund/khosla-ventures) led the $40M Series A in January 2021 with Menlo Ventures (/fund/menlo-ventures) participating.
Earli raised a $40M Series A in January 2021. It is a clinical-stage private biotech.
Most cancers are found too late for curative surgery — Earli's approach could enable detection and localization without waiting for symptoms or invasive biopsies.
No. Earli is privately held and clinical-stage as of July 2026.
Last updated: 2026-07-24